Autism Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Verified date | March 2019 |
Source | Forest Laboratories |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this randomized withdrawal study is to evaluate the safety, tolerability, and efficacy of memantine compared with placebo in pediatric patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).
Status | Completed |
Enrollment | 479 |
Est. completion date | October 2013 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 12 Years |
Eligibility |
Inclusion Criteria: 1. Completed at least 12 weeks of exposure to study drug in lead-in study MEM-MD-91 (NCT01592786) 2. Met responder criterion at two consecutive visits separated by at least two weeks in lead-in study MEM-MD-91 3. Provide written informed assent, when developmentally appropriate, to participate in the study before conduct of any study-specific procedures. The parent/guardian/LAR must provide written informed consent before the patient's participation in the study. A separate written informed consent for the caregiver must also be obtained before the conduct of any study specific procedures 4. Have a knowledgeable caregiver who is capable of providing reliable information about the patient's condition, attending all clinic visits with the patient, and overseeing the administration of study drug. Every effort should be made to maintain the same caregiver as used in the lead-in study throughout this study 5. Have normal results from the physical examination, laboratory tests, ECG, and vital signs at Visit 1 of this study (last visit of Study MEM-MD-91). Any abnormal findings must be deemed not clinically significant by the Investigator and documented 6. Be able to speak and understand English sufficiently (or their native language if this can be accommodated by the site), as well as have a caregiver and parent/guardian/LAR who is able to speak and understand English sufficiently (or their native language if this can be accommodated by the site), to comprehend the nature of the study and to allow for the completion of all study assessments 7. Have a family that is sufficiently organized and stable to guarantee adequate safety monitoring and continuous attendance to clinic visits for the duration of the study 8. Females who are 9 years and older or who have had onset of menses must have a negative urine pregnancy test at Visit 1 9. Age of 6 years to 12 years at the time of entry into lead in study MEM-MD-91 Exclusion Criteria: 1. Patients with a concurrent medical condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger the patient's well being 2. Significant risk of suicidality based on the Investigator's judgment, the Aberrant Behavior Checklist-Irritability subscale (ABC-I), or if appropriate, as indicated by a response of "yes" to questions 4 or 5 in the suicidal ideation section of the Children's C-SSRS (Columbia-Suicide Severity Rating Scale) or any suicidal behavior. 3. Patients with evidence or history of malignancy (other than excised basal cell carcinoma) or any significant hematologic, endocrine, cardiovascular (including any rhythm disorder), neurologic, respiratory, renal, hepatic, or gastrointestinal disease 4. Female patients of child-bearing potential who are not using or not willing to use a conventional method of contraception approved by the PI. Abstinence is an acceptable method of contraception 5. Patients requiring treatment with prohibited concomitant medications 6. Patients who, in the opinion of the Investigator, might not be suitable for the study 7. Employee or immediate relative of an employee of Forest Laboratories, Inc., any of its affiliates or partners, or the study center |
Country | Name | City | State |
---|---|---|---|
Belgium | Forest Investigative Site 204 | Brussel | |
Belgium | Forest Investigative Site 203 | Bruxelles | |
Colombia | Forest Investigative Site 228 | Bello | |
Colombia | Forest Investigative Site 226 | Bogotá | |
Estonia | Forest Investigative Site 276 | Tallinn | |
France | Forest Investigative Site 329 | Bron Cedex | |
Hungary | Forest Investigative Site 376 | Budapest | |
Hungary | Forest Investigative Site 378 | Budapest | |
Hungary | Forest Investigative Site 381 | Budapest | |
Iceland | Forest Investigative Site 401 | Kopavogur | |
Italy | Forest Investigative Site 453 | Roma | |
Italy | Forest Investigative Site 452 | Siena | |
Korea, Republic of | Forest Investigative Site 701 | Seoul | |
Korea, Republic of | Forest Investigative Site 702 | Seoul | |
Korea, Republic of | Forest Investigative Site 703 | Seoul | |
Korea, Republic of | Forest Investigative Site 704 | Yangsan-si | Gyeongsangnam-do |
New Zealand | Forest Investigative Site 526 | Wellington | |
Poland | Forest Investigative Site 578 | Gdansk | |
Poland | Forest Investigative Site 579 | Gdansk | |
Poland | Forest Investigative Site 576 | Kobierzyce | |
Poland | Forest Investigative Site 577 | Warszawa | |
Serbia | Forest Investigative Site 626 | Belgrade | |
Serbia | Forest Investigative Site 627 | Belgrade | |
Serbia | Forest Investigative Site 629 | Nis | |
Serbia | Forest Investigative Site 628 | Novi Sad | |
South Africa | Forest Investigative Site 676 | Cape Town | Western Cape |
Spain | Forest Investigative Site 728 | Sabadell | Barcelona |
Ukraine | Forest Investigative Site 807 | Kharkiv | |
Ukraine | Forest Investigative Site 802 | Kherson,Vil. Stepanivka | |
Ukraine | Forest Investigative Site 804 | Kyiv | |
United States | Forest Investigative Site 081 | Albuquerque | New Mexico |
United States | Forest Investigative Site 107 | Albuquerque | New Mexico |
United States | Forest Investigative Site 069 | Avon Lake | Ohio |
United States | Forest Investigative Site 071 | Bothell | Washington |
United States | Forest Investigative Site 078 | Boulder | Colorado |
United States | Forest Investigative Site 075 | Bradenton | Florida |
United States | Forest Investigative Site 073 | Centennial | Colorado |
United States | Forest Investigative Site 072 | Chapel Hill | North Carolina |
United States | Forest Investigative Site 105 | Charleston | South Carolina |
United States | Forest Investigative Site 119 | Charleston | West Virginia |
United States | Forest Investigative Site 064 | Charlottesville | Virginia |
United States | Forest Investigative Site 028 | Clinton | Utah |
United States | Forest Investigative Site 001 | Columbus | Ohio |
United States | Forest Investigative Site 068 | Dothan | Alabama |
United States | Forest Investigative Site 082 | Evansville | Indiana |
United States | Forest Investigative Site 080 | Gainesville | Florida |
United States | Forest Investigative Site 054 | Glendale | California |
United States | Forest Investigative Site 053 | Gresham | Oregon |
United States | Forest Investigative Site 130 | Henderson | Nevada |
United States | Forest Investigative Site 051 | Houston | Texas |
United States | Forest Investigative Site 109 | Imperial | California |
United States | Forest Investigative Site 056 | Indianapolis | Indiana |
United States | Forest Investigative Site 117 | Jacksonville | Florida |
United States | Forest Investigative Site 132 | Johnstown | Pennsylvania |
United States | Forest Investigative Site 095 | Lake Charles | Louisiana |
United States | Forest Investigative Site 104 | Las Vegas | Nevada |
United States | Forest Investigative Site 102 | Libertyville | Illinois |
United States | Forest Investigative Site 097 | Lincoln | Nebraska |
United States | Forest Investigative Site 116 | Lincoln | Nebraska |
United States | Forest Investigative Site 077 | Little Rock | Arkansas |
United States | Forest Investigative Site 096 | Los Angeles | California |
United States | Forest Investigative Site 061 | Louisville | Kentucky |
United States | Forest Investigative Site 065 | Maitland | Florida |
United States | Forest Investigative Site 131 | McMurray | Pennsylvania |
United States | Forest Investigative Site 100 | Media | Pennsylvania |
United States | Forest Investigative Site 090 | Memphis | Tennessee |
United States | Forest Investigative Site 118 | Miami | Florida |
United States | Forest Investigative Site 063 | Middleton | Wisconsin |
United States | Forest Investigative Site 023 | Naperville | Illinois |
United States | Forest Investigative Site 057 | Nashville | Tennessee |
United States | Forest Investigative Site 136 | Neptune | New Jersey |
United States | Forest Investigative Site 059 | Newton | Massachusetts |
United States | Forest Investigative Site 113 | Norfolk | Virginia |
United States | Forest Investigative Site 085 | Oakland Park | Florida |
United States | Forest Investigative Site 141 | Ogden | Utah |
United States | Forest Investigative Site 019 | Oklahoma City | Oklahoma |
United States | Forest Investigative Site 115 | Orange City | Florida |
United States | Forest Investigative Site 062 | Orlando | Florida |
United States | Forest Investigative Site 125 | Orlando | Florida |
United States | Forest Investigative Site 005 | Phoenix | Arizona |
United States | Forest Investigative Site 086 | Rockville | Maryland |
United States | Forest Investigative Site 029 | Salt Lake City | Utah |
United States | Forest Investigative Site 021 | San Francisco | California |
United States | Forest Investigative Site 026 | Santa Ana | California |
United States | Forest Investigative Site 108 | Springfield | Massachusetts |
United States | Forest Investigative Site 002 | Stanford | California |
United States | Forest Investigative Site 067 | Tampa | Florida |
United States | Forest Investigative Site 070 | The Woodlands | Texas |
United States | Forest Investigative Site 127 | Toms River | New Jersey |
United States | Forest Investigative Site 055 | Tucson | Arizona |
United States | Forest Investigative Site 092 | Tulsa | Oklahoma |
United States | Forest Investigative Site 052 | Washington | District of Columbia |
United States | Forest Investigative Site 101 | Wellington | Florida |
United States | Forest Investigative Site 106 | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
Forest Laboratories |
United States, Belgium, Colombia, Estonia, France, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases) | Loss of Therapeutic response is defined as a worsening (increase) of at least 10 points in Social Responsiveness Scale (SRS) total raw score relative to the Visit 1 (randomization) score. The Social Responsiveness Scale (SRS) is a 65-item informant-rated assessment with total raw score ranging from 0 (no impairment) to 195 (severe social impairment). Each item is associated with 1 of 5 subscales (social awareness, social cognition, social communication, social motivation and autistic mannerisms). Each item is rated on a 4-point scale from 1 (not true) to 4 (almost always true). The scores are then transposed to a scale from 0 to 3 and scores are summed within each of the 5 subscales. A higher score indicates greater severity of social impairment. | Baseline (Visit 1) to week 12 | |
Secondary | Time to First Loss of Therapeutic (LTR) Response | Time to the first visit when a patient shows LTR following randomization to memantine or placebo. | Baseline to week 12 | |
Secondary | Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Speech Subscale at Week 12 | The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Speech Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). | Baseline (Visit 1) to week 12 | |
Secondary | Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 12 | The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Syntax Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). | Baseline (Visit 1) to week 12 | |
Secondary | Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale at Week 12 | The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Semantics Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). | Baseline (Visit 1) to week 12 | |
Secondary | Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale at Week 12 | The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Coherence Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). | Baseline (Visit 1) to week 12 | |
Secondary | Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale at Week 12 | The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Initiation Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). | Baseline (Visit 1) to week 12 | |
Secondary | Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale at Week 12 | The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Scripted language Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). | Baseline (Visit 1) to week 12 | |
Secondary | Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Context Subscale at Week 12 | The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Context Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). | Baseline (Visit 1) to week 12 | |
Secondary | Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale at Week 12 | The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Nonverbal communication Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). | Baseline (Visit 1) to week 12 | |
Secondary | Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale at Week 12 | The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Social Relations Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). | Baseline (Visit 1) to week 12 | |
Secondary | Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Interests Subscale at Week 12 | The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Interests Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). | Baseline (Visit 1) to week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05302167 -
Molehill Mountain Feasibility Study.
|
N/A | |
Completed |
NCT04167839 -
Effects of Sensory Diets on Children's Sensory Processing Skills, Psychosocial Skills, and Classroom Engagement
|
N/A | |
Terminated |
NCT04049981 -
Investigation of Mechanisms of Action in Superpower Glass
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06080087 -
Implementation Toolkit to Enhance EBP Among Marginalized Families
|
N/A | |
Recruiting |
NCT04107064 -
Achieving Steady Work Among Adults With Autism Through Specialized Employment Program
|
N/A | |
Completed |
NCT03206996 -
Exposure Therapy for Auditory Sensitivity in Autism
|
N/A | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Completed |
NCT05588570 -
Coaching Children With Anxiety and Autism Through Telehealth
|
N/A | |
Enrolling by invitation |
NCT06058104 -
Evaluating Efficacy of a Digital Game Therapeutic for Children With Autism
|
N/A | |
Completed |
NCT03002363 -
The Effects of Video Modeling of Audiological Testing on Pediatric Patient Compliance
|
Phase 1 | |
Withdrawn |
NCT02414451 -
Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response
|
N/A | |
Completed |
NCT02911194 -
a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT02847182 -
Cord Blood Infusion for Children With Autism Spectrum Disorder
|
Phase 2 | |
Completed |
NCT02708290 -
Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
|
||
Completed |
NCT02508922 -
Trial of Vitamin D3 Supplementation in Paediatric Autism
|
N/A | |
Completed |
NCT02720900 -
Prebiotic Intervention for Autism Spectrum Disorders
|
N/A | |
Completed |
NCT02536365 -
Sensory Integration Therapy in Autism: Mechanisms and Effectiveness
|
N/A | |
Recruiting |
NCT02255565 -
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
|
Phase 4 | |
Recruiting |
NCT01836562 -
A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism
|
Phase 1/Phase 2 | |
Completed |
NCT02154828 -
Clinical Evaluation of Integrative Practices Units Infant and Child Care for Unit Children With Typical or Atypical Autism (AUTISM)
|